A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease
عنوان الدراسة
A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease
داعم الدراسة
Global Therapeutics Inc
دواء الدراسة
Osivelotor
رقم بروتوكول الدراسة
C5351004 (GBT021601)
حالة الدراسة
Ongoing
موقع الدراسة
Prince Mohammad Bin Naser Hospital (Jazan), King Abdulaziz Medical City NG (Riyadh)
مرحلة الدراسة
2/3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.